Issue of Equity

RNS Number : 4347H

Physiomics PLC

27 May 2011

 



Physiomics plc

("Physiomics" or the "Company")

Issue of Equity

Physiomics plc announces today that following the receipt of notice of exercise of employee options, 2,500,000 Ordinary Shares of 0.04p each in the Company (the "Options Shares") have now been issued at a price of 0.4p each.

Application has been made to admit the Option Shares to trading on AIM, and dealings in the Option Shares are expected to commence on 3 June 2011.

Following the issue of the Option Shares, the total number of shares now in issue is 1,128,550,074 Ordinary Shares.

Enquiries:

Physiomics plc

Dr. Mark Chadwick, CEO

[phone]

WH Ireland Limited

Katy Mitchell

[phone]

Information on Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behavior to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million¹.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

¹Tufts Centre Impact Report 2002

 

END

 

 

IOEEANSXADAFEEF